Vitrolife completes acquisition of Cryo Management Ltd
On June 29 Vitrolife announced that the company had entered into an agreement to acquire 100% ownership in Cryo Management Ltd. Vitrolife has now completed the transaction and Cryo Management Ltd is now a part of Vitrolife.
Cryo Management Ltd is one of the world’s leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. The company has approximately 20 employees and is based in Hungary. The acquisition was completed under essentially the same conditions as were communicated on June 29.
“We are pleased to be able to welcome our new colleagues within Cryo to the Vitrolife Group. There continues to be great and increasing interest in the market for the company’s product for the monitoring of embryos, Primo Vision, and we look forward to being able to offer this world-leading product to current and new customers,” says Thomas Axelsson, CEO.
October 4, 2012
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, phone 46 31 721 80 01
Mikael Engblom, CFO, phone 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 4, 2012 at 4:30 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is a global biotechnology/medical device Group. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
